{"nctId":"NCT01198275","briefTitle":"n-3 Polyunsaturated Fatty Acids (PUFAs) in the Prevention of Atrial Fibrillation","startDateStruct":{"date":"2006-01"},"conditions":["Atrial Fibrillation"],"count":199,"armGroups":[{"label":"n-3 PUFAs","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: n-3 PUFAs","Drug: RASS inhibitors and/or RAS blockers","Drug: Amiodarone"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: RASS inhibitors and/or RAS blockers","Drug: Amiodarone"]}],"interventions":[{"name":"n-3 PUFAs","otherNames":["OMACOR"]},{"name":"Placebo","otherNames":[]},{"name":"RASS inhibitors and/or RAS blockers","otherNames":["renin-angiotensin-aldosterone system inhibitor"]},{"name":"Amiodarone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* persistent Atrial Fibrillation (AF) lasting \\> one month\n* history of at least one AF relapse after previous electrical or Pharmacological cardioversion\n\nExclusion Criteria:\n\n* left atrium size \\> 6 cm\n* severe valvulopathy\n* myocardial infarction during the previous 6 months\n* unstable angina\n* NYHA heart failure class IV or hemodynamic instability\n* cardiac surgery during the previous 3 months\n* significant pulmonary thyroid and hepatic disease\n* contraindications to treatment with amiodarone or RASS inhibitors\n* chronic renal dysfunction\n* QT \\> 480 msec in the absence of bundle-branch block\n* bradycardia \\< 50 b/min\n* diagnosis of paroxysmal AF\n* hyperkalemia\n* pregnancy\n* any disease or other medical treatment that, in the opinion of the investigators, could interfere with the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"The Mean Time to a First Recurrence of AF and the Rate of AF Recurrence","description":"The mean time to a first recurrence of AF; and the rate of AF recurrence at 1, 3 and 6 months.","classes":[]},{"type":"PRIMARY","title":"Probability of Maintenance of Sinus Rhythm at One-year Follow up.(Number of Patients Who Maintained Sinus Rhythm)","description":"Sinus Rhythm maintenance means no Atrial Fibrillation recurrence at one-year follow up. Patients with successful electrical cardioversion (DCCV)underwent weekly clinical and electrocardiographic controls for the first three weeks following cardioversion. Subsequently, follow up visits with performance of clinical evaluation, ECG, and a 24-hour Holter monitoring were performed at 1, 3, 6 and 12 months after DCCV.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":[]}}}